Abstract

The present disclosure provides an apparatus and a method for manufacturing a composite. In one aspect, the present disclosure provides a method for manufacturing a formulation comprising a first component and a second component. This method includes: a step for preparing a series of flow paths in which a first flow path through which a first fluid flows at a first flow velocity and a second flow path through which a second fluid flows at a second flow velocity are combined at a merging portion to form a third flow path through which a third fluid flows at a third flow velocity; a step in which the first component is injected into the first flow path at a first time; and a step in which the second component is injected into the second flow path at a second time. The first time and the second time are set so that the first component and the second component reach the merging portion at a timing when the components are mixed.

IPC Classes  ?

• B01F 23/45 - Mixing liquids with liquids; Emulsifying using flow mixing
• A61K 9/127 - Liposomes
• B01F 25/43 - Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
• B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
• B01F 35/22 - Control or regulation
• B01F 35/71 - Feed mechanisms
• B01F 35/75 - Discharge mechanisms
• B01F 35/92 - Heating or cooling systems for heating the outside of the receptacle, e.g. heated jackets or burners
• B01F 35/213 - Measuring of the properties of the mixtures, e.g. temperature, density or colour
• B01F 35/221 - Control or regulation of operational parameters, e.g. level of material in the mixer, temperature or pressure
• B01J 2/10 - Processes or devices for granulating materials, in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions

Abstract

The present invention addresses the problem of providing: a protein that acts as a scintillator; and a method for designing a protein that acts as a scintillator. According to the present invention, a use of a β-barrel-type fluorescent protein as a scintillator is provided, wherein the β-barrel-type fluorescent protein has a fluorescence peak at 500 nm or less. According to the present invention, a method for designing a protein that acts as a scintillator is also provided, the method comprising (A) a step for identifying a specific amino acid residue in an amino acid sequence for a β-barrel-type fluorescent protein being mutated and (B) a step for constructing, on the basis of the amino acid sequence for the protein being mutated, an amino acid sequence having a structure such that the amino acid residue identified in the step (A) is substituted by another specific amino acid residue.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 1/13 - Unicellular algae; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/12 - Genes encoding animal proteins
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present disclosure provides an apparatus and a method for taking out a particular fraction from a flow path. More particularly, in one aspect, the present disclosure provides a method for taking out a particular fraction from a flow path. The method includes: a step for flowing a component through the flow path; a step for taking out a fraction from the collection part on the flow path by means of a dispenser provided with a valve; and a step for distributing the fraction to the receiving part. In one embodiment, the collection part is positioned in a middle portion of the flow path (a portion that is neither an inflow port nor an outflow port of the flow path).

IPC Classes  ?

• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• A61K 9/127 - Liposomes
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• B01F 23/45 - Mixing liquids with liquids; Emulsifying using flow mixing
• B01F 25/43 - Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
• B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
• B01F 35/75 - Discharge mechanisms
• B01F 35/213 - Measuring of the properties of the mixtures, e.g. temperature, density or colour
• B01F 35/221 - Control or regulation of operational parameters, e.g. level of material in the mixer, temperature or pressure
• B01J 2/10 - Processes or devices for granulating materials, in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
• B01J 4/00 - Feed devices; Feed or outlet control devices
• B01J 13/02 - Making microcapsules or microballoons
• B01F 101/04 - Mixing biocidal, pesticidal or herbicidal ingredients used in agriculture or horticulture, e.g. for spraying
• B01F 101/06 - Mixing of food ingredients
• B01F 101/21 - Mixing of ingredients for cosmetic or perfume compositions
• B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions

Abstract

This sterilization device (1) comprises: a first container (12) that accommodates an object (A01); a first decompression unit (14) that decompresses the first container; and a supply unit (15) that supplies a pernitric acid gas to the object placed under a decompressed condition provided by the first decompression unit. The sterilization device can sterilize deep portions of the object.

IPC Classes  ?

• A61L 2/20 - Gaseous substances, e.g. vapours

Abstract

Provided is a wavelength conversion element in which high-quality crystal part can be utilized by a simple configuration. This wavelength conversion element comprises a substrate having a main surface, and an optical waveguide disposed on the main surface of the substrate, a core of the optical waveguide including a polar member having a second-order nonlinear optical constant and a first non-polar member disposed adjacent to the polar member in a direction parallel to the main surface of the substrate, and one or both side surfaces of the polar member and the first non-polar member being in contact with each other in a cross section orthogonal to the optical axis of the optical waveguide.

IPC Classes  ?

• G02F 1/377 - Non-linear optics for second-harmonic generation in an optical waveguide structure

Abstract

Provided is a biomarker useful for the diagnosis of cancer and the development of new drugs. Further provided are a cancer examination method, a treatment agent, and a reagent for studies of cancer, in each of which the biomarker is used. A useful biomarker is provided by identifying a protein that is expressed on the surface of the membrane of an extracellular vesicle (EV) in a cancer-specific manner. The cancer examination method includes detecting a protein (biomarker) that is expressed, in a cancer-specific manner, on the surface of the membrane of an EV contained in a collected body fluid specimen to detect a cancer-specific EV. An antibody against a protein expressed on the surface of the membrane of an EV in a cancer-specific manner can be used in a cancer examination method, a cancer treatment agent, and a reagent for studies of cancer.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Provided is a method for detecting an abnormal cell having a gene mutation, the method comprising: a step for amplifying a region corresponding to a region comprising a nucleotide sequence lying between a nucleotide located at position-1,316 and a nucleotide located at position-1,663 in SEQ ID NO:1 and/or a region corresponding to a region comprising a nucleotide sequence lying between a nucleotide located at position-1,931 and a nucleotide located at position-2,642 in SEQ ID NO: 1 to produce an amplification product, wherein SEQ ID NO:1 is included in genomic DNA derived from a peripheral blood mononuclear cell of the patient; and a step for determining the nucleotide sequence for the amplification product and detecting a nucleotide mutation. In the method, the presence of the lesion is indicated when the nucleotide mutation is detected, and the amplification is performed by a PCR using a primer having no additional sequence.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The purpose is to provide a novel luminescence-related gene (nucleic acid, vector for expression) capable of imparting stronger luminescence than by known luminescence-related genes to an organism (in particular, a plant).　Provided is a nucleic acid containing at least one base sequence selected from: a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 1 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 1; a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 2 or 3 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 2 or 3; a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 4 or 5 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 4 or 5; and a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 6 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 6.

IPC Classes  ?

• C12N 15/53 - Oxidoreductases (1)
• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
• A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 5/04 - Plant cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/55 - Hydrolases (3)
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

One purpose of the present invention is to provide a resin film and a metal-clad laminate, each of which enables the production of a printed wiring board that has excellent dimensional stability, while being reduced in transmission loss. Another purpose of the present invention is to provide a method for producing a resin film that enables the production of a printed wiring board that has excellent dimensional stability, while being reduced in transmission loss. The present invention relates to a resin film 7 which comprises a polyimide film 70 and a PTFE film 71 that is directly superposed on the polyimide film 70. With respect to the resin film 7, the peeling strength at the time when the PTFE film 71 is peeled is 0.5 N/mm or more.

IPC Classes  ?

• B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
• B29C 65/02 - Joining of preformed parts; Apparatus therefor by heating, with or without pressure
• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising acrylic resin
• B32B 27/34 - Layered products essentially comprising synthetic resin comprising polyamides
• C08J 7/00 - Chemical treatment or coating of shaped articles made of macromolecular substances
• H05K 1/03 - Use of materials for the substrate

Abstract

A welding inspection method includes a step S102 of removing an impurity at a surface of a weld with a surface treatment apparatus, a step S110 of irradiating the surface of the weld from which the impurity has been removed with transmission laser light, a step S120 of detecting reflected ultrasound reflected by a lower surface of a base material, and a step S150 of determining whether or not there is an internal defect in the weld based on a result of detection of reflected ultrasound.

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• B23K 31/12 - Processes relevant to this subclass, specially adapted for particular articles or purposes, but not covered by any single one of main groups relating to investigating the properties, e.g. the weldability, of materials
• G01N 33/2045 - Defects
• G01N 33/207 - Welded or soldered joints; Solderability

Abstract

A permanent magnet-type rotary electric machine comprises: a stator including: a stator core having a plurality of stator teeth formed circumferentially; stator coils arranged in the respective bottoms of a plurality of stator slots formed between the stator teeth and wound on the stator teeth in a concentrated winding manner; and stator magnets arranged near the respective openings of the plurality of stator slots, a first rotor having a plurality of pole pieces and disposed coaxially with the stator to face the stator magnets; and a second rotor having a plurality of permanent magnets and disposed coaxially with the first rotor to face the first rotor, wherein the circumferential width of stator teeth positioned between the adjacent two of the stator magnets is narrower than the circumferential width of the stator slots.

IPC Classes  ?

• H02K 1/16 - Stator cores with slots for windings
• H02K 1/17 - Stator cores with permanent magnets
• H02K 16/02 - Machines with one stator and two rotors

Abstract

An additive manufacturing apparatus includes: a chamber; a gas supply device that supplies an ambient gas into the chamber; an irradiation device that irradiates a molding region with an energy beam in order to mold a three dimensional molding object, the molding region being provided with a powder bed fusion on which a powder is spread in the chamber; and a controller that performs control related to additive manufacturing of the molding object, wherein the controller is configured to increase a pressure of the ambient gas in the chamber to be higher than an atmospheric pressure when the molding object is molded.

IPC Classes  ?

• B22F 10/322 - Process control of the atmosphere, e.g. composition or pressure in a building chamber of the gas flow, e.g. rate or direction
• B22F 10/28 - Powder bed fusion, e.g. selective laser melting [SLM] or electron beam melting [EBM]
• B22F 12/70 - Gas flow means
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

This boron compound is represented by formula (1). In formula (1), X1and X2are each independently selected from among electron-withdrawing groups, Y1and Y2are each independently selected from among hydrogen and electron-donating groups, with hydrogen not being selected for both simultaneously, R1 is selected from among C1-24 organic groups, the C1-24 organic group may have a substituent, and n is selected from among the integers from 0 to 2.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• B01J 31/22 - Organic complexes
• C07B 31/00 - Reduction in general
• C07B 37/02 - Addition
• C07B 37/12 - Diels-Alder reactions
• C07B 61/00 - Other general methods
• C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom

Abstract

In a method for creating isotope distribution data, samples for analysis having different concentrations of metabolites are prepared as samples containing metabolites of cells cultured in a medium containing a substrate labeled with a stable isotope, mass spectrometry is performed on each under the same analysis condition, mass spectrum data is analyzed for each to identify the type of the metabolites, and there are determined the number of metabolites included in a metabolite group made of unlabeled metabolites and/or isotopic isomers, and the signal intensities of mass peaks corresponding to all isotope isomers included in the metabolite group. The number of metabolites corresponding to all types of metabolites and the signal intensity are compared among the samples to select a sample for analysis for obtaining the isotope distribution, and data on the isotope distribution of the metabolite is integrated to create the isotope distribution data of the metabolite.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

A method for separating components using a supercritical fluid chromatograph, including: injecting a sample into a mobile phase containing a supercritical fluid and a modifier to introduce the sample into a column; and separating components in the sample during passing through the column; wherein the sample contains an oligonucleotide as a target component; the supercritical fluid contains carbon dioxide; and the modifier contains a solution containing at least one selected from the group consisting of ammonium, an alkylamine, and an amino alcohol, and an acid.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• B01D 15/40 - Selective adsorption, e.g. chromatography characterised by the separation mechanism using supercritical fluid as mobile phase or eluent

Abstract

Provided is a technique for examining an autoimmune disease. This method for examining an autoimmune disease involves (1) a step for examining the presence or absence of endogenous human herpesvirus 6B in genomic DNA of a biological sample sampled from a subject.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C12N 15/09 - Recombinant DNA-technology

Abstract

A solid state welding apparatus comprises a pair of compression bars, a pair of electrodes disposed around the pair of compression bars, respectively, and a controller. The controller passes a first current through the pair of electrodes while controlling the pair of compression bars to cause a first load to act on each of first and second workpieces to bring the workpieces into contact with each other, and subsequently passes a second current larger than the first current through the pair of electrodes while controlling the pair of compression bars to cause a second load to act on each of first and second workpieces.

IPC Classes  ?

• B23K 11/30 - Features relating to electrodes
• B23K 11/24 - Electric supply or control circuits therefor

Abstract

A wall thickness estimation method includes: obtaining behavioral information that is based on a video in which an organ wall or a blood vessel wall is captured using four-dimensional angiography, the behavioral information being numerical information about changes over time in a position of each of a plurality of predetermined points in the organ wall or the blood vessel wall; generating estimation information using a model trained to take as an input an image indicating a physical parameter based on the behavioral information obtained in the obtaining and output an index indicating a thickness at each of the plurality of predetermined points in the organ wall or the blood vessel wall, the estimation information being information visualizing the thickness; and outputting the estimation information generated in the generating.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume

Abstract

A resistance spot joining method includes: a protrusion forming step of forming a protrusion on at least one of a first workpiece and a second workpiece by pressing the first and second workpieces with a first load by a pressing shaft and a pressing member; a load reducing step of reducing an area of contact between the first and second workpieces by reducing a pressing force from the pressing shaft and the pressing member such that a second load is applied to the first and second workpieces; a current applying step of applying a current to the first and second workpieces; and a joining step of joining contact interfaces of the first and second workpiece to each other by pressing the first and second workpieces with a third load.

IPC Classes  ?

• B23K 11/11 - Spot welding
• B23K 11/24 - Electric supply or control circuits therefor
• B23K 11/36 - Auxiliary equipment

Abstract

A solid state welding apparatus comprises a pair of compression bars, a pair of electrodes disposed around the pair of compression bars, respectively, and a controller. The controller controls the pair of compression bars to cause a first load to act on each of the first and second workpieces, subsequently controls the pair of compression bars to subject compressive force to load removal to cause a second load smaller than the first load to act on the first and second workpieces, and subsequently passes a current through the pair of electrodes to remove an impurity on a metal surface.

IPC Classes  ?

• B23K 11/11 - Spot welding
• B23K 11/30 - Features relating to electrodes
• B23K 103/00 - Materials to be soldered, welded or cut

Abstract

A structured illumination microscope according to the present embodiment comprises: an excitation light source for generating excitation light; an activation light source that generates activation light to activate a fluorescent substance; an objective lens that focuses the excitation light onto a sample S; a structured illumination optical system that illuminates the sample using the excitation light as a structured illumination pattern; an activation optical system that irradiates the sample with activation 2 through the objective lens; and an imaging optical system that detects fluorescence generated at the sample via the objective lens to capture a fluorescent image of the sample.

IPC Classes  ?

• G02B 21/06 - Means for illuminating specimen
• G01N 21/64 - Fluorescence; Phosphorescence
• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes

Abstract

This soldering device comprises: a solder joint part-forming device that has a soldering iron and forms a solder joint part in a soldering target area; an imaging device that images the solder joint part formed in the target area from a prescribed direction; an illumination device that illuminates the solder joint part formed in the target area from the prescribed direction; and a control device. The control device: causes the imaging device to perform imaging in a state in which the illumination device is providing illumination, thereby obtaining a first image of the solder joint part; causes the imaging device to perform imaging in a state where the illumination device has stopped illuminating, thereby obtaining a second image of the solder joint part; creates a brightness difference image which indicates a difference in brightness between the first image and the second image; and makes a determination about an excess failure and/or a shortage failure of the solder joint part, on the basis of the brightness difference image.

IPC Classes  ?

• B23K 1/00 - Soldering, e.g. brazing, or unsoldering

Abstract

Provided are an information processing method, a computer program, an information processing system, and an information terminal device that achieve safe and effective circulation of medical data. An information processing method according to the present invention involves a computer executing processing that receives a purchase condition for a set of non-fungible tokens (NFTs) issued for access to the medical data of patients, outputs retrieval results for a set of NFTs that match the received purchase condition and a sales condition for the retrieved set of NFTs, receives a purchase request that designates a set of NFTs to be purchased from the retrieval results, transfers the set of NFTs to a purchaser in response to the purchase request, and gives compensation that corresponds to the transfer of the set of NFTs to the registrant registered to each of the NFTs included in the set.

IPC Classes  ?

• G06Q 30/0601 - Electronic shopping [e-shopping]
• G16H 70/00 - ICT specially adapted for the handling or processing of medical references

Abstract

Y1-YX1-x1-xN, and on which the Group III nitride semiconductor layer, the active layer, and the electron blocking layer are mounted, wherein X is greater than 0 and less than or equal to 1. In the active layer, the Al composition G is equal to or greater than Y but less than (Y+0.04), and the compositional difference between the maximum Al composition of the electron blocking layer and the Al composition of the active layer is 0.18 or more.

IPC Classes  ?

• H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
• H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth

Abstract

Disclosed is a bispecific antibody that recognizes CCR8 as an antigen. It was found that the bispecific antibody has cytotoxic activity against CCR8-expressing cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/46 - Hybrid immunoglobulins
• C12N 15/13 - Immunoglobulins
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

Provided are: a coating composition which has enhanced coatability and solubility in solvents and contains POSS with alkyl groups introduced; a method for producing a coated article using the coating composition; and a produced coated article. The present invention relates to a coating composition containing a silsesquioxane derivative which has a silsesquioxane skeleton having a polyhedral structure and in which a plurality of alkyl groups having different numbers of carbon atoms are bonded to silicon atoms. The coating composition can be applied to a substrate to produce a coated article. This produced coated article has a substrate and a coating, formed on the surface of the substrate, that contains a silsesquioxane derivative which has a silsesquioxane skeleton having a polyhedral structure and in which a plurality of alkyl groups having different numbers of carbon atoms are bonded to silicon atoms.

IPC Classes  ?

• C09D 183/04 - Polysiloxanes

Abstract

Provided are a graphene biosensor having high resistance to foreign substances while maintaining ultra-high sensitivity characteristics of graphene, and a method for using the graphene biosensor. Provided is a graphene biosensor 1 for detecting a measurement object gas 200 included in a liquid sample 100, wherein the graphene biosensor comprises: a substrate 10; a graphene layer 30 provided on the substrate 10, comprising at least one layer of graphene, and having a graphene layer principal surface 32 on the liquid sample 100 side; a drain electrode 21 electrically connected to the graphene layer 30; a source electrode 22 electrically connected to the graphene layer 30; and a gas-permeable layer 40 that comprises a gas-permeable material that transmits the measurement object gas 200, covers the graphene layer principal surface 32, and has a permeable layer principal surface 42 on the liquid sample 100 side.

IPC Classes  ?

• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

[Problem] To provide a method for detecting the quantity of a first structure and the quantity of a second structure, the method comprising a step for detecting the quantity of a bonded first label and the quantity of a bonded second label together. [Solution] Provided is a method for detecting the quantity of a first structure and the quantity of a second structure, the method comprising: a step for bonding a first label to a first structure; a step for releasing a second structure from the first structure; a step for boding a second label to the second structure; and a step for detecting the quantity of the bonded first label and the quantity of the bonded second label together, wherein the second structure is included in the first structure, and the first label and the second label can be detected together, but are different.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Provided is a functional device that enables at least one among measuring the activity of tissue of a living body with high resolution and applying fine stimulation to tissue of a living body, while being minimally invasive. This functional device 1 is indwelled inside a blood vessel of a living body and performs at least one among measurement of the activity of tissue outside the blood vessel and stimulation to the tissue. The functional device 1 comprises: a sheet-like flexible substrate 3; at least one functional part formed on the substrate 3; and a wiring 12 formed on the substrate 3 and connected to the functional part, wherein at least one among at least a portion of the surface of the substrate 3 and at least a portion of the surface of the functional part is covered with an antithrombotic material.

IPC Classes  ?

• A61B 5/37 - Intracranial electroencephalography [IC-EEG], e.g. electrocorticography [ECoG]
• A61B 5/293 - Invasive

Abstract

The present invention provides a device and a method for predicting the ability to implant in the uterus of a mother, and a device and a method for estimating delivery timing. This device for predicting the ability to implant in the uterus of a subject comprises: an electrode that is inserted up to a position which is either in the uterine cavity or intravaginal cavity of the subject; a measurement means for measuring the bioelectrical impedance at the position; and a prediction means for predicting the ability to implant, using the measured bioelectrical impedance value as an index. A device for estimating the delivery timing of the subject according to the present invention comprises: an electrode that is brought into contact with the mucosal epithelium at a position in the uterine cavity or intravaginal cavity of the subject; a measuring means of measuring the bioelectric impedance generated between the electrode and the mucosal epithelium; and an estimation means of estimating the delivery timing of the subject using the measured value of the bioelectric impedance as an index.

IPC Classes  ?

• A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
• A61B 5/0538 - Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter

Abstract

Disclosed is a pharmaceutical composition for treating and/or preventing central neuropathic pain, the pharmaceutical composition containing at least one component selected from the group consisting of a JAK/STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor. Also disclosed is a pharmaceutical composition for treating and/or preventing neuropathic pain, the pharmaceutical composition containing at least one component selected from the group consisting of a JAK/STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor and being to be administered at intervals of 6 days or more.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/277 - Nitriles; Isonitriles having a ring, e.g. verapamil
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

The present invention provides a single-round infectious rotavirus characterized by having a mutation in at least one viral protein of the rotavirus, which is selected from the group consisting of VP1, VP2, VP3, VP4, VP6, VP7, NSP2, NSP3, and NSP4. The single-round infectious rotavirus according to the present invention can be used in a rotavirus vaccine, a rotavirus neutralization test method, and the like.

IPC Classes  ?

• C12N 15/46 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
• A61K 39/15 - Reoviridae, e.g. calf diarrhea virus
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 7/04 - Inactivation or attenuation; Producing viral sub-units
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Abstract

Provided is a method for producing a high-purity vascular endothelial cell population from a biological tissue or an organ, the method including: using a culture vessel having a structure in which a culture medium in a first culture vessel and a culture medium in a second culture vessel can be in contact with each other via a porous membrane having pores for cell permeation; coating the culture surface of the first culture vessel with an extracellular matrix including a vascular endothelial cell migration factor; filling the first and second culture vessels with the culture medium; initiating the culture of the biological tissue or the organ in the second culture vessel; and recovering the cells that have passed through the porous membrane and have moved into the first culture vessel. Also provided is a medicine containing the vascular endothelial cell population produced by said method as an active ingredient.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

A control system (100) controls an operation target (2). The control system (100) comprises a detection unit (3), a first determination unit (43), a second determination unit (44), and a weight determination unit (45). The detection unit (3) detects a detection target related to autonomous control of the operation target (2). The first determination unit (43) determines the next action of the operation target (2) by voluntary control, on the basis of brain waves of an operator (P) who operates the operation target (2). The second determination unit (44) determines the next action of the operation target (2) by the autonomous control, on the basis of the detection result from the detection unit (3). The weight determination unit (45) determines, on the basis of the detection result from the detection unit (3), a first weight for the next action of the operation target (2) by the voluntary control, and a second weight for the next action of the operation target (2) by the autonomous control. The weight determination unit (45) changes the first weight and the second weight in accordance with the detection result from the detection unit (3).

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06F 3/048 - Interaction techniques based on graphical user interfaces [GUI]
• B25J 13/00 - Controls for manipulators

Abstract

Provided is an efficient method for producing semiconductor nanoparticles that exhibit band edge emission. The method comprises performing a first heat treatment of a first mixture, which contains a Cu salt, a Ag salt, a salt containing at least one of In or Ga, a gallium halide, and an organic solvent, to obtain first semiconductor nanoparticles. At least one of the Cu salt, the Ag salt, or the salt containing at least one of In or Ga in the first mixture contains a compound having a bond formed of a metal and sulfur.

IPC Classes  ?

• H01L 33/50 - Wavelength conversion elements
• C01G 15/00 - Compounds of gallium, indium, or thallium
• C09K 11/62 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing gallium, indium or thallium

Abstract

The present invention pertains to: an anti-APLP1 monoclonal antibody of which the epitope is the amino acid sequence from no. 232 to no. 238 in SEQ ID NO. 1; and an anti-APLP1 monoclonal antibody in which CDR1, CDR2, and CDR3 in a light chain respectively have the amino acid sequences described in SEQ ID NO. 5, 7, and 9, and CDR1, CDR2, and CDR3 in a heavy chain respectively have the amino acid sequences described in SEQ ID NO. 12, 14, and 16. The present invention also pertains to: a method for recovering extracellular vesicles derived from brain neurons by using the anti-APLP1 monoclonal antibody of the present invention; methods for detecting a neuropsychiatric disease biomarker and for recovering neuron-derived components, the methods each comprising recovering extracellular vesicles by said method; and a test reagent and a test kit which are for use in recovering extracellular vesicles and which include the anti-APLP1 monoclonal antibody of the present invention. The present invention provides: an anti-APLP1 monoclonal antibody having a higher specificity with respect to NDE; a method for recovering extracellular vesicles by using said antibody; a method for detecting a neuropsychiatric disease biomarker using the recovered extracellular vesicles; a test drug; and a test kit.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/079 - Neural cells
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

This adeno-associated virus (AAV) vector particle contains a capsid, wherein: the capsid includes capsid proteins VP1, VP2, and VP3; the VP3 is (A) a polypeptide consisting of the amino acid sequence set forth in one among SEQ ID NOs: 1-6 and 25-29 or (B) a polypeptide which consists of an amino acid sequence that includes deletion, substitution, addition, or a combination thereof in the amino acid sequence of the (A) polypeptide and shares a sequence identity of at least 80% with an amino acid sequence corresponding to the 18th-533rd positions of the amino acid sequence set forth in SEQ ID NO: 1 and from which the capsid can be formed; and the ratio ([VP1+VP2]/[VP3]) of the number of the VP1 and the VP2 to the number of the VP3 in the capsid is at least 0.3.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms

Abstract

A water treatment method for recovering a specific substance dissolved in water being treated, wherein a working electrode W configured from an organic redox substance provided with selective adsorption capacity with respect to a specific substance is immersed in water being treated, the specific substance is electrochemically adsorbed to the working electrode W, the working electrode to which the specific substance is adsorbed is immersed in a recovery solution, and the specific substance is electrochemically discharged from the working electrode W, whereby a useful specific substance such as ammonia contained in wastewater can be safely and efficiently recovered.

IPC Classes  ?

• C02F 1/48 - Treatment of water, waste water, or sewage with magnetic or electric fields

Abstract

A support apparatus includes an irradiation device for emitting a particle beam, a detection device for detecting a particle beam irradiation region, and a control unit for acquiring the irradiation region. The control unit specifies an attention region within the irradiation region in a treatment plan for a patient, and specifies the irradiation position for pre-irradiation within the attention region. The control unit instructs the irradiation device to carry out pre-irradiation with irradiation energy in the treatment plan at the irradiation position, and acquires the irradiation region detected by the detection device. The control unit further adjusts irradiation conditions in the treatment plan according to the irradiation region in the pre-irradiation and instructs the irradiation device to carry out post-irradiation under the adjusted irradiation conditions.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

Provided is a polymer that has an aliphatic polyester resin skeleton and has excellent performance in strength while being biodegradable. The polymer has a cyclodextrin skeleton as a side chain of the polymer, and has a fatty acid polyester resin structure in at least one section.

IPC Classes  ?

• C08G 63/08 - Lactones or lactides
• C08F 20/28 - Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
• C08F 20/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08G 18/66 - Compounds of groups , , or

Abstract

According to one embodiment, an alignment processing device includes a light source, a polarizing beam splitter, a first optical system, a second optical system, a first retardation film, a second retardation film, a moving mechanism configured to move a processing substrate in which a thin film is formed, and a controller. Interfering light is formed in an exposure area by first circularly polarized light and second circularly polarized light. The controller performs control so as to repeat a process of exposing part of an area of the thin film by the interfering light and a process of moving the processing substrate.

IPC Classes  ?

• G02F 1/1337 - Surface-induced orientation of the liquid crystal molecules, e.g. by alignment layers
• G02F 1/1335 - Structural association of cells with optical devices, e.g. polarisers or reflectors

Abstract

This confocal imaging device comprises: a light source that generates illumination light; a multi-pinhole plate that is disposed at a position conjugate to the sample and has a plurality of pinholes; a drive mechanism that drives the multi-pinhole plate; an objective lens that condenses the illumination light from the multi-pinhole plate onto the sample and into which signal light from the sample is incident; an imaging lens that is disposed between the objective lens and the multi-pinhole plate and forms an image of the signal light from the sample on the multi-pinhole plate; a beam splitter that causes the signal light that has passed through the pinholes to branch from the illumination light; a telecentric lens into which the signal light is incident; and an imaging device that detects the signal light from the telecentric lens and images the sample.

IPC Classes  ?

• G02B 21/00 - Microscopes
• G01N 21/64 - Fluorescence; Phosphorescence
• H04N 1/04 - Scanning arrangements
• H04N 1/10 - Scanning arrangements using flat picture-bearing surfaces

Abstract

A chuck apparatus is configured to hold a wafer during planarization of the wafer with the aid of anodizing. The chuck apparatus includes a chuck cover, a suction portion, and an energizing portion. The suction portion includes a suction surface that suctions the wafer. The energizing portion is provided in the suction portion so as to come into contact and energize the wafer suctioned by the suction portion. The chuck cover covers the suction portion and the energizing portion in an insulating manner while exposing the suction surface.

IPC Classes  ?

• H01L 21/683 - Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereof; Apparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components for supporting or gripping

Abstract

The present inventors identified many nuclear proteins contained in the extract of skin tissue by mass spectrometry, randomly selected multiple partial amino acid sequences of the nuclear proteins, chemically synthesized peptides consisting of the partial amino acid sequences, and examined their activity of mobilizing mesenchymal stem cells. As a result, it was found that these multiple peptides show the activity of mobilizing mesenchymal stem cells into peripheral blood, even though their amino acid sequences are completely different from each other. The inventors also found that fragment peptides of the nuclear proteins have therapeutic effects on diseases characterized by inflammation and abnormalities of the immune system (e.g., inflammatory bowel disease and psoriasis). Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 17/06 - Antipsoriatics
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

A medicine recommendation apparatus (2000) acquires disease information (20), gene mutation information (30), and current medication information (40). The disease information (20) is information regarding a disease that a subject suffers from. The gene mutation information (30) is information regarding a gene mutation of the subject. The current medication information (40) is information regarding a medicine that the subject is using. The medicine recommendation apparatus (2000) generates candidate medicine information (10) by using the disease information (20), the gene mutation information (30), and the current medication information (40). The candidate medicine information (10) is information regarding a candidate for a medicine use of which can be recommended to the subject or which can be prescribed to the subject.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Abstract

Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 19/00 - Hybrid peptides
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology

Abstract

A composition comprising skeletal myoblasts for treating liver dysfunction or improving liver function, in which the liver dysfunction can be hepatitis, liver fibrosis, liver cirrhosis, liver cancer, or liver failure. The composition can be used for promoting the proliferation of liver cells, regeneration of the liver tissue and/or angiogenesis, and providing a method for treating liver dysfunction, including a step of treating applying the composition to a site exhibiting liver dysfunction.

IPC Classes  ?

• A61K 35/34 - Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

This method for joining metal materials includes: a preparation step for superposing in a predetermined direction a first material to be joined including a first metal and a second material to be joined including a second metal; a heating step for heating a joint interface between the first material and the second material, and/or a first portion located in the vicinity of the joint interface in the first material, and/or a second portion located in the vicinity of the joint interface in the second material; and a joining step for applying toward the joint interface a pressure along a predetermined direction for joining together the first material and the second material. In the heating step, a current running along a direction intersecting the predetermined direction is passed through the joint interface, and/or the first portion, and/or the second portion.

IPC Classes  ?

• B23K 20/00 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating

Abstract

The present invention relates to a cell structure production method comprising a step in which a plurality of cells including at least epithelial cells and vascular endothelial cells are cultured in a culture medium containing one or more growth factors that contribute to angiogenesis.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention provides a compound which is capable of selectively delivering a cell to a disease site such as a bone or a tooth. The compound comprises a hydrophilic polymer or a derivative thereof, a bile acid or a derivative thereof, and a hydroxyapatite-directed substance which has a photolytic protective group. Also provided is a cell which has adsorbed the compound.

IPC Classes  ?

• C08G 85/00 - General processes for preparing compounds provided for in this subclass
• A61K 31/65 - Tetracyclines
• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/32 - Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
• A61K 35/545 - Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/38 - Animal cells
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• C08F 16/06 - Polyvinyl alcohol
• C08G 65/48 - Polymers modified by chemical after-treatment

Abstract

[Problem] The present invention addresses the problem of providing an agent for preventing and/or treating amyotrophic lateral sclerosis. [Solution] This agent for preventing and/or treating amyotrophic lateral sclerosis contains at least one compound selected from the group consisting of paclitaxel, docetaxel, carfilzomib, olaparib, and nicotinamide.

IPC Classes  ?

• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
• A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 38/07 - Tetrapeptides
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The purpose of the present invention is to provide a novel technique for manufacturing a bonded structure by direct bonding. A bonded structure in which a structure 1 and a structure 2 are bonded with a metal plating film interposed therebetween is provided.

IPC Classes  ?

• H01L 21/60 - Attaching leads or other conductive members, to be used for carrying current to or from the device in operation
• H01L 21/52 - Mounting semiconductor bodies in containers

Abstract

The present application discloses a glycolipid derivative (I) represented by formula (I) (wherein each symbol is as described in the description) or a salt thereof as one of the embodiments of the invention, the glycolipid derivative (I) or a salt thereof being useful as a novel ligand for a macrophage-inducible C-type lectin receptor.

IPC Classes  ?

• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

12122 are platinum and molybdenum, platinum and rhenium, platinum and tungsten, rhodium and molybdenum, or palladium and molybdenum.*

IPC Classes  ?

• C07C 209/46 - Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acids or esters thereof in presence of ammonia or amines
• B01J 23/652 - Chromium, molybdenum or tungsten
• B01J 23/656 - Manganese, technetium or rhenium
• B01J 27/18 - Phosphorus; Compounds thereof containing oxygen with metals
• B01J 27/19 - Molybdenum
• C07B 61/00 - Other general methods
• C07C 211/03 - Monoamines
• C07C 211/05 - Mono-, di- or tri-ethylamine
• C07C 211/07 - Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
• C07C 211/35 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
• C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• C07D 211/46 - Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
• C07D 211/58 - Nitrogen atoms attached in position 4
• C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
• C07D 265/30 - 1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
• C07D 273/01 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups having one nitrogen atom
• C07D 295/03 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
• C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C07D 295/023 - Preparation; Separation; Stabilisation; Use of additives
• C07D 295/067 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
• C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 307/14 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

Provided is a low-temperature-sintering bonding material that is easy to prepare and that, when used for sintering bonding, enables sintering at low temperatures and can provide highly reliable bonded structures. A low-temperature-sintering bonding material according to an embodiment contains silver particles and silicon particles, and more than 50% of the surface of the silicon particles is composed of silicon atoms. A low-temperature-sintering bonding material according to another embodiment contains silver particles and silicon particles, wherein sintering brings about the formation of an interface at the atomic level between the silver constituting the silver particles and the silicon constituting the silicon particles.

IPC Classes  ?

• H01L 21/52 - Mounting semiconductor bodies in containers
• H01B 1/00 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors
• H01B 1/22 - Conductive material dispersed in non-conductive organic material the conductive material comprising metals or alloys

Abstract

Provided are: a method for friction-joining galvanized steel sheets in which admixture of zinc into a joined part is effectively suppressed, and with which it is possible to obtain a joined part that is coated with a galvanized layer; and a joined structure obtained through the aforementioned joining method. A friction-joining method characterized by having a first step for bringing one member into contact with another member to form a joining interface, a second step for repeatedly causing the one member and the other member to slide on the same trajectory in a state in which pressure is applied substantially perpendicularly to the joining interface and eliminating burrs from the joining interface, and a third step for stopping the sliding and forming a joined surface, the friction-joining method also being characterized in that the one member and/or the other member is configured as a galvanized steel sheet, and in that admixture of a galvanized component into the joined surface is suppressed due to the elimination of the burrs.

IPC Classes  ?

• B23K 20/12 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating the heat being generated by friction; Friction welding
• B23K 103/04 - Steel alloys

Abstract

Provided are a method for producing a protein material without using an organic solvent, the method involving ejecting a solution containing a protein material raw material into a water-based medium and drying the ejected protein material raw material, and a protein material produced by the method.

IPC Classes  ?

• C08H 1/06 - Macromolecular products derived from proteins derived from horn, hoofs, hair, skin, or leather
• C08L 89/06 - Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin
• D01F 4/00 - Monocomponent artificial filaments or the like of proteins; Manufacture thereof

Abstract

Provided is a linear friction welding method wherein, at the timing at which a newly formed surface of a first welding member 11A and a newly formed surface of a second welding member 11B make contact due to burr 12 discharge, a second pressure P2 that is greater than a first pressure P1 is applied to a welding interface such that base material parts of the first welding member 11A and the second welding member 11B which are continuous with a weld part 13 plastically deform so as to spread toward the welding interface M.

IPC Classes  ?

• B23K 20/12 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating the heat being generated by friction; Friction welding

Abstract

Disclosed, inter alia, is: a method for introducing a nucleic acid and/or protein into cells, the method comprising a step for bringing cells into contact in vitro with a lipid nanoparticle in which a nucleic acid and/or protein is internally sealed, the cells being at a stage from fertilized egg to blastula; and a method for producing cells into which a nucleic acid and/or a protein has been introduced and that are at a stage from fertilized egg to blastula, the method comprising a step for bringing cells into contact in vitro with a lipid nanoparticle in which a nucleic acid and/or protein is internally sealed, the cells being at a stage from fertilized egg to blastula.

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues

Abstract

Provided is a metal sheet having excellent handleability, suppressed void formation during bonding, and excellent bondability. A metal sheet 1 according to an embodiment of the present invention has, on at least one surface (surface 31a and/or 32a), a region in which grains having an area of 40,000 nm2 or less constitute at least 50% of the surface area. In addition, the metal sheet 1 according to another embodiment of the present invention has an internal porosity of 70% or less, and has, on at least one surface (surface 31a and/or 32a), a region having a porosity of 20% or less in the vicinity of the surface and having sinterability.

IPC Classes  ?

• B22F 5/00 - Manufacture of workpieces or articles from metallic powder characterised by the special shape of the product
• B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder
• H01B 5/02 - Single bars, rods, wires or strips; Bus-bars

Abstract

The method of the present invention for evaluating the risk of developing liver cancer in a subject includes (1) a step of measuring a GDF15 level of a subject and (2) a step of relating the GDF15 level to the risk of developing liver cancer. When the GDF15 level measured in step (1) is not less than a cutoff value set in advance, the GDF15 level becomes an indicator that the subject has a high risk of developing liver cancer, and when the GDF15 level is less than the cutoff value, it becomes an indicator that the risk of developing liver cancer is low. The present invention also provides a kit for measuring GDF15 levels in a subject for use in the method of the present invention, and a diagnostic agent for evaluating the risk of developing liver cancer in a subject, which contains an anti-GDF15-specific antibody.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

xpsxpsxpsxpsxps ≤ 0.300.

IPC Classes  ?

• C01B 32/00 - Carbon; Compounds thereof
• B01J 27/24 - Nitrogen compounds
• B01J 35/60 - characterised by their surface properties or porosity
• C25B 11/031 - Porous electrodes
• C25B 11/043 - Carbon, e.g. diamond or graphene
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• H01M 4/96 - Carbon-based electrodes
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cells; Manufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode

Abstract

A carbon material according to the present invention includes a fired product of a phthalocyanine compound that includes bromine as a substituent.

IPC Classes  ?

• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• B01J 27/24 - Nitrogen compounds
• B01J 37/08 - Heat treatment
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/054 - Electrodes comprising electrocatalysts supported on a carrier
• C25B 11/085 - Organic compound
• C25B 11/095 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one of the compounds being organic
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte

Abstract

This composite material comprises a carbon material and a zinc phthalocyanine halide fixed on the surface of the carbon material.

IPC Classes  ?

• B01J 31/22 - Organic complexes
• B01J 37/04 - Mixing
• C01B 15/029 - Preparation from hydrogen and oxygen
• C25B 11/031 - Porous electrodes
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/054 - Electrodes comprising electrocatalysts supported on a carrier
• C25B 11/065 - Carbon
• C25B 11/085 - Organic compound

Abstract

The present invention provides: a rare-earth-doped semiconductor device which has further improved EQE %, while having excellent emission intensity; and a method for producing the rare-earth-doped semiconductor device. A rare-earth-doped semiconductor device in which an active layer that is obtained by adding a rare earth element to a base material that is composed of GaN, InN, AlN or an alloy compound semiconductor of any two or more of these compounds is arranged between an n-type layer and a p-type layer, wherein a p-type doped layer in which a p-type dopant is added together with a rare earth element is formed in the p-type layer side of the active layer. A method for producing a rare-earth-doped semiconductor device, wherein: formation of an n-type layer, formation of an active layer and formation of a p-type layer are performed by a series of formation steps under the temperature conditions of 900° C. to 1200° C. with use of an organic metal vapor deposition method without being taken out of a reaction vessel; and when the active layer is formed, a p-type doped layer is formed in the p-type layer side of the active layer by adding a p-type dopant together with a rare earth element.

IPC Classes  ?

• H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
• H01S 5/30 - Structure or shape of the active region; Materials used for the active region
• H01S 5/323 - Structure or shape of the active region; Materials used for the active region comprising PN junctions, e.g. hetero- or double- hetero-structures in AIIIBV compounds, e.g. AlGaAs-laser

Abstract

An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Provided are a method and a reaction vessel for efficiently performing a chemical reaction. The method comprises: charging a mixed solution containing a polar solute and a non-polar solute into a reaction vessel; separating the mixed solution into a first solution layer mainly containing the polar solute and a second solution layer mainly containing the non-polar solute in the reaction vessel; and emitting light outside the reaction vessel toward the interface between the first solution layer and the second solution layer mainly through one of the first solution layer and the second solution layer that has a lower light absorption rate, to cause a chemical reaction of the polar solute with the non-polar solute. The reaction vessel, into which a mixed solution containing a polar solute and a non-polar solute is to be charged, is provided with a light guide unit that is disposed so as to cause light outside the reaction vessel to enter the reaction vessel and be emitted toward the interface between a first solution layer mainly containing the polar solute and a second solution layer mainly containing the non-polar solute, mainly through one of the first solution layer and the second solution layer that has a lower light absorption rate.

IPC Classes  ?

• B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves

Abstract

The purpose of the present invention is to provide a composition for inducing follicular helper T cells reactive with SARS-CoV-2. Provided is a partial peptide of a spike protein of SARS-CoV-2, the partial peptide containing an amino acid sequence selected from the group consisting of (1) to (17) below and having a total length of 15 amino acids or less: (1) FKIYSKHTPIN (SEQ ID NO: 1); (2) FQFCNDPFLGVYYHK (SEQ ID NO: 2); (3) KRFDNPVLPFN (SEQ ID NO: 3); (4) LLQYGSFCTQL (SEQ ID NO: 4); (5) PPAYTNSFTRGVYYP (SEQ ID NO: 5); (6) CSNLLLQYGSFCTQL (SEQ ID NO: 6); (7) SKRSFIEDLLFNKVT (SEQ ID NO: 7); (8) TGVLTESNKKFLPFQ (SEQ ID NO: 8); (9) TNGTKRFDNPVLPFN (SEQ ID NO: 9); (10) NQFNSAIGKIQ (SEQ ID NO: 10); (11) NFTISVTTEIL (SEQ ID NO: 11); (12) STEIYQAGSTPCNGV (SEQ ID NO: 12); (13) KVFRSSVLHST (SEQ ID NO: 13); (14) EIRASANLAAT (SEQ ID NO: 14); (15) NFTISVTTEILPVSM (SEQ ID NO: 15); (16) FIKQYGDCLGDIAAR (SEQ ID NO: 16); and (17) FIEDLLFNKVTLADA (SEQ ID NO: 17).

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed is a carbon material which contains a fired product of a mixture that contains a first compound and a second compound, wherein: the first compound is a phthalocyanine compound that has bromine as a substituent; and the second compound contains at least one metal element that is selected from the group consisting of Fe, Co, Ni, Cu, Al and Zn.

IPC Classes  ?

• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• B01J 27/24 - Nitrogen compounds
• B01J 37/08 - Heat treatment
• C25B 11/031 - Porous electrodes
• C25B 11/053 - Electrodes comprising one or more electrocatalytic coatings on a substrate characterised by multilayer electrocatalytic coatings
• C25B 11/054 - Electrodes comprising electrocatalysts supported on a carrier
• C25B 11/085 - Organic compound
• C25B 11/095 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one of the compounds being organic
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte

Abstract

Provided are a hydrogen boride-containing composition, a hydrogen generation system, and a fuel cell system that achieve further performance improvement of a hydrogen supply source with a hydrogen boride-containing sheet. The hydrogen boride-containing composition contains a hydrogen boride-containing sheet having a two-dimensional network consisting of (BH)n(n≥4, where n is an integer) and an electron donor. At least a portion of the electron donor is supported on the hydrogen boride-containing sheet, electrons of the electron donor are supplied to the hydrogen boride-containing sheet by external stimulus, and hydrogen is generated from the hydrogen boride-containing sheet into which the electrons are injected.

IPC Classes  ?

• H01M 8/0606 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
• C01B 6/00 - Hydrides of metals; Monoborane or diborane; Addition complexes thereof

Abstract

Semiconductor nanoparticles including Ag, In, Ga, and S are provided. In the semiconductor nanoparticles, a ratio of a number of Ga atoms to a total number of In and Ga atoms is 0.95 or less. The semiconductor nanoparticles emit light having an emission peak with a wavelength in a range of from 500 nm to less than 590 nm, and a half bandwidth of 70 nm or less, and have an average particle diameter of 10 nm or less.

IPC Classes  ?

• H01L 33/50 - Wavelength conversion elements
• C09K 11/62 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing gallium, indium or thallium
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
• H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier

Abstract

This bioelectric potential measurement device is provided with: an electrode sheet that acquires a biological signal; a device having a contact part that connects to the electrode sheet; and a connection member that sandwiches the electrode sheet between the connection member and the device and thereby connects the electrode sheet to the contact part. The connection member has a fitting part that fits to the device, and the electrode sheet has a shape corresponding to the fitting part.

IPC Classes  ?

• A61B 5/25 - Bioelectric electrodes therefor

Abstract

Provided is a method for separating a solid-phase joined body having: a first joined material that is unsuitable for fusion welding; a second joined material; and a joining portion that joins the first joined material and the second joined material. The method comprises a step for heating at least one of the first joined material and the joining portion so that at least one of the first joined material and the joining portion exhibits embrittlement and/or weld cracking.

IPC Classes  ?

• B23P 11/00 - Connecting or disconnecting metal parts or objects by metal-working techniques, not otherwise provided for
• B02C 19/18 - Use of auxiliary physical effects, e.g. ultrasonics, irradiation, for disintegrating
• B23K 20/12 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating the heat being generated by friction; Friction welding
• B23K 20/20 - Special methods allowing subsequent separation, e.g. of metals of high quality from scrap material
• B23K 26/356 - Working by laser beam, e.g. welding, cutting or boring for surface treatment by shock processing

Abstract

Provided is a method for producing a joined member, the method making it possible to achieve dissimilar material joining by a process different from conventional ones. This method for producing a joined member comprises: a roughening step in which the surface of a first metal member (1), which is formed of a metal, is roughened so as to have a nanoscale relief shape by plasma processing without using a mask; and a joining step in which a second metal member (2) or a resin member (3) is joined to the roughened surface of the first metal member.

IPC Classes  ?

• C23F 4/00 - Processes for removing metallic material from surfaces, not provided for in group or
• B23K 20/00 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating

Abstract

Provided is a culture method for maintaining lymphoid-biased hematopoietic stem cells (Ly-HSCs), the method including a step for culturing hematopoietic stem cells (HSCs) in a medium containing CXCL12 and/or an agonist thereof, SCF and/or an agonist thereof, TPO and/or an agonist thereof, and a vinyl polymer.

IPC Classes  ?

• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C07K 14/52 - Cytokines; Lymphokines; Interferons
• C12N 1/00 - Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor

Abstract

[Problem] To provide an inexpensive means that makes it possible to monitor the state of the heart of a subject such as a patient with less invasiveness than before without substantially compromising reliability in acquiring heart sound. [Solution] In a wearable device 2 that is worn on a wrist of a subject for use, a sound collection unit, which has a rubber 623, for acquiring the heart sound of the subject is disposed on an upper surface 201, and a user interface unit 65 that is used by the subject is disposed on a side surface 204 along the longitudinal direction of the arm of the subject when the wearable device 2 is worn on the wrist of the subject.

IPC Classes  ?

• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/01 - Measuring temperature of body parts
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements

Abstract

It was found that DNA greater than 100 bp can be deleted in one of homologous chromosomes by generating a plurality of nicks in a DNA region in the vicinity of a specific site in the homologous chromosomes. As an example of medical applications, it was found that destruction specific to Col7a gene having a heterozygous mutation causing dystrophic epidermolysis bullosa can be caused.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology

Abstract

This dental composition contains a glass powder composite, the glass powder composite including a first glass powder and a second glass powder having solubility different from that of the first glass powder by pH, both the first glass powder and the second glass powder having ion sustained release properties.

IPC Classes  ?

• A61K 6/77 - Glass
• A61K 6/836 - Glass

Abstract

The present invention predicts a condition from which a characteristic value of a target material can be obtained. A method according to one embodiment of the present invention comprises: acquiring a characteristic value of a material; inversely analyzing a model for predicting the characteristic value of the material from a feature amount of the material, and thereby predicting the feature amount of the material from the acquired characteristic value of the material; generating phase data analysis results on the basis of the predicted feature amount of the material; and indicating, on an image of a material different from the material, a pixel corresponding to a portion designated in the phase data analysis results.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G01N 3/20 - Investigating strength properties of solid materials by application of mechanical stress by applying steady bending forces

Abstract

Provided are a novel silicone-based polymer compound with excellent mechanical properties and a silicone-based polymer material containing the silicone-based polymer compound. The silicone-based polymer compound of the present invention is a silicone-based polymer compound (H) having a polysiloxane backbone as the main chain, wherein the polysiloxane backbone has at least one host group in a side chain, and the host group is a monovalent group formed by removing one hydrogen atom or one hydroxy group from a cyclodextrin or a cyclodextrin derivative.

IPC Classes  ?

• C08G 77/38 - Polysiloxanes modified by chemical after-treatment
• C08B 37/16 - Cyclodextrin; Derivatives thereof

Abstract

The present invention accurately infers the presence or absence of a disease. An information processing device (1A) comprises: an image acquisition unit (11) that acquires an image that has captured therein a target site of a subject to which a radiopharmaceutical has been administered; a variation index calculation unit (51) that calculates, on the basis of the image, a variation index (23) indicating the degree of variation in radiation dose at the target site, the radiation dose being emitted from the radiopharmaceutical accumulated in the target site of the subject; and an inference unit (12) that infers a disease at the target site of the subject on the basis of the calculated variation index (23).

IPC Classes  ?

• G01T 1/161 - Applications in the field of nuclear medicine, e.g. in vivo counting
• G06T 7/00 - Image analysis

Abstract

Provided is a three-dimensional mammary gland model comprising a three-dimensional tissue containing cells and fragmented extracellular matrix components, wherein the cells include mature fat cells and mammary gland epithelial cells.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Provided are: a polymer material which is tough but can be easily decomposed; a method for producing the same; and a method for decomposing the polymer material.　This polymer material comprises: a polymer composition containing a polymer compound H; and a photoacid generator. The polymer compound H has at least one host group in the molecule. The host group is obtained by removing one hydrogen atom or hydroxyl group from cyclodextrin or a cyclodextrin derivative, and is covalently bonded to the polymer compound H via a hemiaminal bond.

IPC Classes  ?

• C08L 101/06 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups containing oxygen atoms
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising acrylic resin
• C08B 37/16 - Cyclodextrin; Derivatives thereof
• C08F 290/10 - Polymers provided for in subclass
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C09J 11/06 - Non-macromolecular additives organic
• C09J 105/16 - Cyclodextrin; Derivatives thereof

Abstract

The present disclosure provides inducible regulatory T cells having high functionality and a stable immunosuppressive function. The present disclosure provides inducible regulatory human T cells having at least one characteristic selected from the group consisting of FoxP3+, CTLA4+, NT5E+, ITGAE (CD103)+, AREG+, CD172g+, and CD26+, and a cell population containing the same. The present disclosure also provides a composition containing such cells, a pharmaceutical composition containing such cells, methods of using the composition and pharmaceutical composition, etc.

IPC Classes  ?

• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 7/06 - Antianaemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disorders; Contraceptives
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• A61P 37/08 - Antiallergic agents

Abstract

The present invention provides a biomarker for predicting prognosis in a sepsis patient, the biomarker comprising IL-1β and TNF-α. The index for predicting the prognosis in a sepsis patient is the blood concentration ratio of IL-1β with respect to TNF-α.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C12N 15/25 - Interleukin-1
• C12N 15/28 - Tumor necrosis factors
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/6869 - Methods for sequencing

Abstract

The present invention provides an organoid characterized by comprising a layered structure of a sheet-like retinal pigment epithelial cell layer and a layer containing visual cells. The present invention also provides a method for producing an organoid, the method comprising: (1) a step for inducing differentiation of retinal progenitor cells from pluripotent stem cells; and (2) a step for carrying out adherent culture of the obtained retinal progenitor cells using a medium containing at least either a serum-free supplement or serum.

IPC Classes  ?

• C12N 5/079 - Neural cells
• A61K 35/30 - Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• A61K 35/36 - Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
• A61P 27/02 - Ophthalmic agents
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The present invention provides a method for separating or concentrating nanodiamond (ND) particles having a group-14 color center that comprises: irradiating a dispersion liquid containing mixed particles of ND particles having a color center (a group-14 color center) of any one group 14 element selected from the group consisting of Si, Ge, Sn, and Pb and ND particles not having the group-14 color center with laser light having an energy equal to or greater than the resonant absorptive energy of the group-14 color center; and selectively moving the ND particles having the group-14 color center by means of light pressure generated by resonant absorption of the laser light.

IPC Classes  ?

• C01B 32/28 - After-treatment, e.g. purification, irradiation, separation or recovery
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C09K 11/65 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing carbon

Abstract

Provided are: a solid-state joining method with which it is possible to control the discharge direction of burrs and to realize sufficient joining strength; a solid-state joined joint and a solid-state joined structure that are obtained through the solid-state joining method; and a solid-state joining device that can be suitably used in the solid-state joining method. A solid-state joining method characterized by having a first step for bringing end parts of one material being joined and another material being joined into butting contact with one another and forming a joining interface, a second step for increasing the temperature in the vicinity of the joining interface by using an external heating means, and a third step for plastically deforming the joining interface to thereby discharge burrs and form a solid-state joined interface, the plate thickness of the end part of the one material being joined and/or the other material being joined is reduced, and the solid-state joining method having a gradient such that the plate thickness decreases on a side where discharge of the burrs is suppressed.

IPC Classes  ?

• B23K 20/12 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating the heat being generated by friction; Friction welding
• B23K 103/04 - Steel alloys
• B23K 103/10 - Aluminium or alloys thereof
• B23K 103/12 - Copper or alloys thereof

Abstract

An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

IPC Classes  ?

• A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides a pharmaceutical composition for treating arthrosis, the pharmaceutical composition comprising a composition containing extracellular vesicles derived from a culture supernatant of mesenchymal stem cells. The pharmaceutical composition is characterized in that a culture medium for the mesenchymal stem cells satisfies the following requirements (1) and (2): (1) the culture medium is a chemically defined medium that does not contain a component derived from an animal of a different species from a subject to be treated; and (2) the number of microparticles each having a particle diameter of 1 to 1000 nm is less than 1×109 particles/mL before use.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells

Abstract

Provided is a technique to carry out mass spectrometry of a wide variety of subject compounds to be analyzed, each of which is extracted in a supercritical fluid. A mass spectrometer (1) includes: a supercritical fluid introduction section (3) for introducing and releasing, to vacuum, a supercritical fluid in which a subject compound for mass spectrometry is contained (extracted); an ionization section (4) that ionizes the subject compound which is extracted in the supercritical fluid, the ionization being carried out in the vacuum by a molecular reaction involving proton transfer; and a mass measurement section (5) that measures a mass of the subject compound which has been ionized.

IPC Classes  ?

• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 30/02 - Column chromatography
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
• H01J 49/14 - Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers
• H01J 49/26 - Mass spectrometers or separator tubes

Abstract

The present invention makes it possible, even when the electrode arrangement is different from a predetermined electrode arrangement, to obtain a necessary multi-channel biological signal. A biological-signal-processing system according to the present disclosure is provided with: m electrodes that are attached to a living body in a first arrangement; and a signal-processing device that executes a process of inputting a p-channel first biological signal acquired from the m electrodes into a generation model and outputting a q-channel second biological signal from the generation model. The q-channel second biological signal is a signal corresponding to a signal obtained from n (n is an integer of 3 or more) electrodes attached to the living body in a second arrangement. The second arrangement is an electrode arrangement different from the first arrangement in terms of at least one of the number of electrodes and the attachment positions. The generation model is configured to output a q-channel second biological signal when a p-channel first biological signal is input.

IPC Classes  ?

• A61B 5/327 - Generation of artificial ECG signals based on measured signals, e.g. to compensate for missing leads

Abstract

The present invention addresses the problem of providing a method for identifying an optical isomer of a low-molecular-weight compound, the method making it possible to analyze whether the optical isomer is in a D-form or an L-form for each measured low-molecular-weight compound. This method for identification comprises: a low-molecular-weight compound electrophoresis step which is performed using a device including measurement electrodes for measuring a tunnel current at the time when a low-molecular-weight compound passes therethrough, and in which a voltage is applied so as to straddle the measurement electrodes of the device, thereby allowing the low-molecular-weight compound contained in a sample solution to pass through the measurement electrodes by electrophoresis; a measurement step in which a tunnel current at the time when the low-molecular-weight compound passes through a gap between the measurement electrodes is measured; and an analysis step in which it is determined, from the measured tunnel current, whether an optical isomer is in a D-form or an L-form for every measured low-molecular-weight compound.

IPC Classes  ?

• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
• G01N 33/483 - Physical analysis of biological material

Abstract

Follicular helper T cells specific to SARS-COV-2 virus are provided. The present disclosure is based on the finding of public TfhTCR specific to spike (S) protein common to various patients, and has identified for the first time a public TCR specific to the SARS-COV-2 virus and its MHC and antigenic epitopes to promote efficient immune responses, particularly those of B cells that produce neutralizing antibodies. For example, the present disclosure provides a composition containing an epitope specific to SARS-COV-2 virus for inducing a follicular T cell.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

An object of this invention is to provide a pharmaceutical composition for preventing and/or treating acute kidney injury, and an autophagy activator. The invention relates to, for example, a pharmaceutical composition for preventing and/or treating acute kidney injury, comprising a compound represented by formula (1), a salt thereof, or a prodrug thereof: An object of this invention is to provide a pharmaceutical composition for preventing and/or treating acute kidney injury, and an autophagy activator. The invention relates to, for example, a pharmaceutical composition for preventing and/or treating acute kidney injury, comprising a compound represented by formula (1), a salt thereof, or a prodrug thereof: wherein A is an optionally substituted benzene ring; B is an optionally substituted aryl or an optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom; of is a single or double bond when Y is a carbon atom, or of is a single bond when Y is a nitrogen atom; each R1 independently represents lower alkyl, or two R1s may be bound to each other to form a spiro ring or a crosslinked structure, or two R1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (R1)p is oxo.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems

Abstract

The present invention provides a drug for preventing and/or treating a disease or condition related to reduced cerebral blood flow, the drug being characterized by containing mammalian vascular endothelial cells positive for the cell surface marker CD157 and being used such that the vascular endothelial cells are delivered intracerebrally. The present invention also provides a drug for cerebral revascularization, the drug characterized by containing mammalian vascular endothelial cells positive for cell surface marker CD157 and being used such that the vascular endothelial cells are delivered intracerebrally.

IPC Classes  ?

• A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• A61K 35/30 - Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - Antiepileptics; Anticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

An analysis device includes an analysis unit configured to receive scattered light, transmitted light, fluorescence, or electromagnetic waves from an observed object located in a light irradiation region light-irradiated from a light source and analyze the observed object on the basis of a signal extracted on the basis of a time axis of an electrical signal output from a light-receiving unit configured to convert the received light or electromagnetic waves into the electrical signal.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• G01N 15/10 - Investigating individual particles
• G01N 15/14 - Electro-optical investigation
• G01N 15/1404 - Handling flow, e.g. hydrodynamic focusing
• G01N 15/1429 - Signal processing
• G01N 15/1434 - Optical arrangements
• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 21/65 - Raman scattering
• G06F 18/21 - Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
• G06F 18/28 - Determining representative reference patterns, e.g. by averaging or distorting; Generating dictionaries
• G06V 10/772 - Determining representative reference patterns, e.g. averaging or distorting patterns; Generating dictionaries
• G06V 10/778 - Active pattern-learning, e.g. online learning of image or video features
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

The present inventors have discovered that a peptide derived from HMGB1 can be used as a therapeutic and/or preventive agent for fatty liver, nonalcoholic steatohepatitis, and various symptoms accompanied by the fatty liver. On the basis of this discovery, the present application provides a use of the peptide derived from HMGB1 which is different from conventional uses.

IPC Classes  ?

• A61K 38/19 - Cytokines; Lymphokines; Interferons
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Provided is a new vaccine against mammal arenavirus infections. This vaccine contains lipid nanoparticles each including mRNA encoding a nucleoprotein (NP) or a glycoprotein precursor (GPC) of arenavirus.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants

Abstract

The present invention provides: a useful production method for a fluoroalkyl aromatic compound; and a compound obtained by the production method. Said production method is for a compound represented by formula (4), and comprises a step C for reacting a compound represented by formula (1) and a compound represented by formula (3), in the presence of a reducing agent, a copper compound, and a ligand. (1): RF-X1(3): Ar-X2(4): Ar-RF(In the formulae, RFrepresents a fluoroalkyl group optionally having at least one substituent, X1represents Cl, Br, or I, X2 represents Cl, Br, or I, and Ar represents an aryl group optionally having at least one substituent or a heteroaryl group optionally having at least one substituent.)

IPC Classes  ?

• C07F 1/08 - Copper compounds
• C07C 17/266 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
• C07C 19/10 - Acyclic saturated compounds containing halogen atoms containing fluorine and chlorine
• C07C 21/18 - Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds containing fluorine
• C07D 471/04 - Ortho-condensed systems